论文部分内容阅读
目的观察多西他赛联合替吉奥新辅助化疗局部晚期胃癌的疗效及安全性。方法 38例局部晚期胃癌第1 d用多西他赛75 mg·m-2;第1～14d替吉奥80 mg·m-2,分2次餐后口服。21 d为1周期,完成3周期后手术。用彩超、CT、手术、病理评价其疗效,评价指标为有效率、中位生存率(OS)、根治手术切除率、病理完全缓解率。结果 38例患者中36例完成3周期化疗,2例2周期后穿孔急诊手术,其中完全缓解(CR)5例,部分缓解(PR)21例,稳定(SD)6例,进展(PD)6例,总有效率68.42%,中位生存率12个月。行根治性切除25例,姑息切除6例,短路术4例,开关术3例。最常见不良反应为骨髓抑制、脱发、胃肠道反应、周围神经毒性。无化疗相关性死亡。结论多西他赛联合替吉奥新辅助化疗局部晚期胃癌具有较好疗效,毒副作用可以耐受。
Objective To observe the efficacy and safety of docetaxel in combination with neoadjuvant chemotherapy for locally advanced gastric cancer. Methods Thirty-eight patients with locally advanced gastric cancer were treated with docetaxel 75 mg · m-2 on day 1 and 80 mg · m-2 on day 14 for oral administration. 21 d for a period of 3 days after the completion of surgery. Efficacy was evaluated by color Doppler ultrasound, CT, operation and pathology. The evaluation indexes were effective rate, median survival rate (OS), radical resection rate and complete pathological response rate. Results Among the 38 patients, 36 patients underwent 3 cycles of chemotherapy and 2 patients underwent 2 cycles of postoperative perforation. There were 5 patients with complete remission (CR), 21 with partial remission (PR), 6 with stable (SD), and 6 with progressive For example, the total effective rate of 68.42%, the median survival rate of 12 months. Radical resection in 25 cases, palliative resection in 6 cases, 4 cases of short-circuit, switch in 3 cases. The most common adverse reactions are myelosuppression, hair loss, gastrointestinal reactions, peripheral neurotoxicity. No chemotherapy-related death. Conclusion Docetaxel combined with tegaserod neoadjuvant chemotherapy for advanced gastric cancer has a good effect, toxic side effects can be tolerated.